ClinicalTrials.gg
CompletedNCT05993897Updated Jul 13, 2026

Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling

An interventional study of Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor and Rhythm control and anticoagulation in Atrial Fibrillation, sponsored by Aswan University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Aswan University · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Atrial Fibrillation with a site in Egypt — 9 open to participants now, 12 under way, 1 of them phase 3. Atrial Fibrillation · Egypt.

Enrollment
18th of 21
60 · median 180
Started
2024
with 5 others
No phase
8 of 33
2 open now
Registered
21st of 33
by date
Lead sponsor
1 of 33
Aswan University

Among the 33 studies in Atrial Fibrillation with a site in Egypt, this one is the 18th largest by enrollment of the 21 interventional ones that give a count, is one of 6 that started in 2024, is one of 8 with no phase, and was the 21st registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

9 of the 33 studies in Atrial Fibrillation with a site in Egypt are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Atrial Fibrillation with a site in Egypt, or all of them as a file.
02

Study summary

Investigators are going to assess direct effect of SGLT2 inhibitors on left atrial remodeling in participants with nonvalvular paroxysmal atrial fibrillation regardless of diabetes status.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. with non-valvular paroxysmal atrial fibrillation (AF that terminates spontaneously or with intervention within seven days of onset).
  2. Patient age 18-60 years.
  3. Patients with (GFR) >45 ml/min/1.73m2 ( equation).
  4. Patient with normal left atrium or dilated (diameter \<5 cm)

Exclusion criteria

Exclusion Criteria:

  1. Patients \< 18 yrs old.
  2. Patients with valvular heart diseases (Moderate to severe MS, severe AS, Prosthetic heart valves).
  3. Patients with left atrium > 5cm.
  4. Patients with (GFR) \<45 ml/min/1.73m2 ( equation).
  5. Patient with ischemic heart disease (previous MI, UA, PCI or CABG).
  6. Patient with previous ischemic stroke.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Dapagliflozin

    patients who will receive SGLT2 inhibitors

    Drug: Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor · Drug: Rhythm control and anticoagulation

  • Placebo comparator
    Placebo

    Patients who will receive Rhythm control +/- oral anticoagulation

    Drug: Rhythm control and anticoagulation

Interventions

  • DrugSodium/Glucose Cotransporter 2Studies of Sodium/Glucose Cotransporter 2Sodium/Glucose Cotransporter 2 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    10 mg of Dapagliflozin orally once daily

  • DrugRhythm control and anticoagulation

    In acute stage: Cardioversion with D.C shock if haemodynamically unstable, after failure of pharmacological cardioversion or participant preference. or pharmacological cardioversion with either IV cordarone in structurally abnormal heart (150mg over 10 minutes followed by1 mg/min infusion for 6 hours followed by 0.5 mg/min not exceeding 2.4 grams over 24 hours till restoration of sinus Rhythm. Then maintenance dose of 200 mg tab orally every 8 hours for 3 weeks then 200 mg tab orally once per day. or Propafenone (Rytmonorm) 600 mg single oral dose in structurally normal heart then maintenance dose of 150mg tab orally every 8 hours. \+ Rivaroxaban 20mg orally once daily if CHA2DS2 VASc score 1 or more for males and 2 or more for females.

06

What researchers measure

Primary outcomes

  1. Left atrial remodeling

    by measuring Indexed LA volume (LAVI) in ml/m2

    Time frame: Before first administration of treatment and will be repeated 6 months after while still on treatment

  2. Changes in left atrial strain

    by measuring left atrial strain %

    Time frame: Before first administration of treatment and will be repeated 6 months after while still on treatment

  3. Changes in left atrial systolic force

    by measuring left atrial systolic force in ml/m3

    Time frame: Before first administration of treatment and will be repeated 6 months after while still on treatment

Secondary outcomes

  1. Mean percentage of time spent in atrial fibrillation

    By documented ECG or Holter monitoring

    Time frame: After the first dose of treatment till the end of the study (1 year)

  2. Mortality Rate

    all cause mortality

    Time frame: After the first dose of treatment till the end of the study (1 year)

  3. Incidence of Hospitalization due to HF

    In hospital admission by HF symptoms

    Time frame: After the first dose of treatment till the end of the study (1 year)

  4. Number of participants with Stroke

    Ischemic or hemorrhagic

    Time frame: After the first dose of treatment till the end of the study (1 year)

07

Study locations

1 site
  • Aswan university
    Aswān, Aswan Governorate, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Jun 2025, 10 months.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 10 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2023
First posted
Aug 15, 2023
StartActual
Aug 20, 2024
Primary completionActual
Jun 30, 2025
CompletionActual
Oct 15, 2025
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05993897
Lead sponsor
Aswan University
Responsible party
Aml Soliman (Lecturer of cardiology, Aswan university, Aswan University) — Principal investigator
First posted
Aug 15, 2023
Start date
Aug 20, 2024
Primary completion
Jun 30, 2025
Completion
Oct 15, 2025
Last update
Jul 13, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium/Glucose Cotransporter 2

Start the discussion